Physician profile
Ginger E Cline
NPI 1518903756
$1,943.72
in general payments reported to CMS, 2019-2025
21 companies · $333 in 2025
The $333 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $177 · 2021: $159 · 2022: $450 · 2023: $254 · 2024: $271 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $834 · Entertainment: $23.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.38 |
| Entertainment | $23.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $330.41 | 2019-2025 | Rocklatan, Clareon, Precision7 |
| Johnson & Johnson Vision Care, INC. | $300.16 | 2019-2025 | Acuvue |
| Coopervision INC. | $187.28 | 2019-2025 | Clariti Contact Lens, Myday Contact Lens |
| Abbvie INC. | $184.16 | 2022-2025 | Xen Glaucoma Treatment System |
| Allergan, INC. | $133.76 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $117.32 | 2019-2021 | |
| Oyster Point Pharma, INC. | $112.10 | 2022-2025 | Tyrvaya |
| Bausch & Lomb Americas INC. | $96.09 | 2022-2025 | Vyzulta, Xiidra |
| Sun Pharmaceutical Industries INC. | $68.02 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $64.82 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $58.55 | 2024-2025 | Xdemvy |
| Abb Con-Cise Optical Group LLC | $52.76 | 2019 | |
| Rxsight INC | $49.15 | 2022-2023 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Optos, INC. | $40.04 | 2019-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Kala Pharmaceuticals, INC. | $39.60 | 2020-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $24.37 | 2023 | |
| Aerie Pharmaceuticals, INC. | $20.21 | 2021 | |
| Mallinckrodt Hospital Products INC. | $19.05 | 2024 | Acthar |
| Shire North American Group INC | $18.70 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $13.64 | 2019 | |
| Genentech USA, INC. | $13.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginger Cline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.